primary central nervous system Hodgkin lymphoma
Showing 1 - 25 of >10,000
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
Lymphoma, Non-Hodgkin, CNS Tumors Trial in Trondheim (18F-FDG, 18F-fluciclovine, standard MRI)
Recruiting
- Lymphoma, Non-Hodgkin
- Central Nervous System Neoplasms
- 18F-FDG
- +2 more
-
Trondheim, NorwayNorwegian University of Science and Technology, Department of Ci
Dec 15, 2021
Primary CNS Hodgkin Lymphoma Trial in Hangzhou (Orelabrutinib, Sintilimab)
Recruiting
- Primary Central Nervous System Hodgkin Lymphoma
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 14, 2021
CNS B-Cell Non-Hodgkin Lymphoma Trial in United States (procedure, biological, other)
Recruiting
- Central Nervous System B-Cell Non-Hodgkin Lymphoma
- Cognitive Assessment
- +2 more
-
Denver, Colorado
- +11 more
Jun 9, 2022
Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)
Recruiting
- Primary Central Nervous System Lymphoma
- +2 more
- Methotrexate
- +2 more
-
Guandong, Guangdong, China
- +2 more
Apr 6, 2022
CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)
Recruiting
- Central Nervous System B-Cell Non-Hodgkin Lymphoma
- +2 more
- Ibrutinib
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)
Recruiting
- Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
- thiotepa combined with pomalidomide
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital.
Jun 27, 2023
Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))
Not yet recruiting
- Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
- intensity-modulated radiotherapy (IMRT)
- (no location specified)
Jun 4, 2023
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)
Completed
- Primary Central Nervous System Lymphoma
- Rituximab
- +2 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022
Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)
Recruiting
- Primary Central Nervous System Lymphoma
- Orelabrutinib
- +2 more
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022
Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)
Active, not recruiting
- Refractory Central Nervous System Lymphoma
- +2 more
-
Hangzhou, Zhejiang, ChinaJianmin Zhang
Jul 3, 2022
Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)
Not yet recruiting
- Primary Central Nervous System Lymphoma
- +3 more
- Pemetrexed
- +3 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 28, 2022
Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)
Recruiting
- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital, Capital Medical University
Jul 31, 2022
Primary CNS Lymphoma Trial in Beijing (Camrelizumab)
Recruiting
- Primary Central Nervous System Lymphoma
-
Beijing, ChinaSanbo Brain Hospital Capital Medical University
Feb 10, 2022
CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma
Active, not recruiting
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- DISEASE
- (no location specified)
May 4, 2023
Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)
Recruiting
- Primary Central Nervous System Lymphoma
- Orelabrutinib,Rituximab and Methotrexate
-
Beijing, Beijing, ChinaHospital 307
Sep 19, 2022
Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)
Recruiting
- Diffuse Large B Cell Lymphoma
- +3 more
- Low-Dose Decitabine plus anti-PD-1
-
Beijing, Beijing, ChinaChinaPLAGH
Apr 18, 2023
Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))
Recruiting
- Primary Central Nervous System Lymphoma
- Glucarpidase
- Methotrexate (MTX)
-
Paris, FranceHôpital Pitié-Salpêtrière
Oct 24, 2022
Primary CNS Lymphoma Trial in Paris (PET-MRI)
Not yet recruiting
- Primary Central Nervous System Lymphoma
-
Paris, FranceHôpital Pitié Salpêtrière
May 20, 2022
Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)
Recruiting
- Primary Central Nervous System Lymphoma
-
Shanghai, Shanghai, ChinaRuijin Hospital
Apr 18, 2022
CNS Lymphoma Trial in Aarhus (Immunochemo)
Completed
- Central Nervous System Lymphoma
-
Aarhus, DenmarkElisa Jacobsen Pulczynski
Aug 3, 2022
Primary CNS Lymphoma Trial in Zhengzhou (the dose-escalation phase)
Recruiting
- Primary Central Nervous System Lymphoma
- the dose-escalation phase
-
Zhengzhou, Henan, ChinaOncology Department of The First Affiliated Hospital of Zhengzho
May 30, 2022